207 related articles for article (PubMed ID: 28472558)
21. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
22. Relationship between p-cofilin and cisplatin resistance in patients with ovarian cancer and the role of p-cofilin in prognosis.
Qin Y; Li W; Long Y; Zhan Z
Cancer Biomark; 2019; 24(4):469-475. PubMed ID: 30932883
[TBL] [Abstract][Full Text] [Related]
23. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
24. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
25. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
26. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.
Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F
Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135
[TBL] [Abstract][Full Text] [Related]
27. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol.
Perego P; Romanelli S; Carenini N; Magnani I; Leone R; Bonetti A; Paolicchi A; Zunino F
Ann Oncol; 1998 Apr; 9(4):423-30. PubMed ID: 9636834
[TBL] [Abstract][Full Text] [Related]
28. Carbon monoxide sensitizes cisplatin-resistant ovarian cancer cell lines toward cisplatin via attenuation of levels of glutathione and nuclear metallothionein.
Kawahara B; Ramadoss S; Chaudhuri G; Janzen C; Sen S; Mascharak PK
J Inorg Biochem; 2019 Feb; 191():29-39. PubMed ID: 30458366
[TBL] [Abstract][Full Text] [Related]
29. Cellular glutathione content, in vitro chemoresponse, and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer.
Lewandowicz GM; Britt P; Elgie AW; Williamson CJ; Coley HM; Hall AG; Sargent JM
Gynecol Oncol; 2002 May; 85(2):298-304. PubMed ID: 11972391
[TBL] [Abstract][Full Text] [Related]
30. Effect of extracellular ATP on cisplatin-induced cytotoxicity in human ovarian carcinoma cells.
Rotte A; Garmann D; Buss I; Jaehde U
Chemotherapy; 2010; 56(1):1-8. PubMed ID: 20185910
[TBL] [Abstract][Full Text] [Related]
31. Sulforaphane enhances the cisplatin sensitivity through regulating DNA repair and accumulation of intracellular cisplatin in ovarian cancer cells.
Gong TT; Liu XD; Zhan ZP; Wu QJ
Exp Cell Res; 2020 Aug; 393(2):112061. PubMed ID: 32437713
[TBL] [Abstract][Full Text] [Related]
32. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
33. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
Behrens BC; Hamilton TC; Masuda H; Grotzinger KR; Whang-Peng J; Louie KG; Knutsen T; McKoy WM; Young RC; Ozols RF
Cancer Res; 1987 Jan; 47(2):414-8. PubMed ID: 3539322
[TBL] [Abstract][Full Text] [Related]
34. Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines.
O'Dwyer PJ; Perez RP; Yao KS; Godwin AK; Hamilton TC
Biochem Pharmacol; 1996 Jul; 52(1):21-7. PubMed ID: 8678904
[TBL] [Abstract][Full Text] [Related]
35. Cross-reacting material 197, a heparin-binding EGF-like growth factor inhibitor, reverses the chemoresistance in human cisplatin-resistant ovarian cancer.
Tang XH; Li M; Deng S; Lu MS
Anticancer Drugs; 2014 Nov; 25(10):1201-10. PubMed ID: 25115341
[TBL] [Abstract][Full Text] [Related]
36. Enhanced gamma-glutamylcysteine synthetase activity decreases drug-induced oxidative stress levels and cytotoxicity.
Das GC; Bacsi A; Shrivastav M; Hazra TK; Boldogh I
Mol Carcinog; 2006 Sep; 45(9):635-47. PubMed ID: 16491484
[TBL] [Abstract][Full Text] [Related]
37. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
Tanaka T; Masuda H; Naito M; Tamai H
Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines.
Holford J; Beale PJ; Boxall FE; Sharp SY; Kelland LR
Eur J Cancer; 2000 Oct; 36(15):1984-90. PubMed ID: 11000581
[TBL] [Abstract][Full Text] [Related]
39. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
40. [Role of apoptosis-associated genes and caspase-3 in cisplatin-resistant human ovarian cancer cell lines].
Yang XK; Xing H; Zheng F; Gao QL; Wang W; Lu YP; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2003 Mar; 38(3):158-61. PubMed ID: 12816691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
